Paper Session I-A - Microencapsulation of Drugs: New cancer therapies and improved drug delivery from microgravity research by Morrison, Dennis R., Ph.D. & Haddad, Ruwaida S., Ph.D.
The Space Congress® Proceedings 2003 (40th) Linking the Past to the Future - A Celebration of Space 
Apr 30th, 1:30 PM - 5:00 PM 
Paper Session I-A - Microencapsulation of Drugs: New cancer 
therapies and improved drug delivery from microgravity research 
Dennis R. Morrison Ph.D. 
Biological Systems Office, NASA Johnson Space Center 
Ruwaida S. Haddad Ph.D. 
Biological Systems Office, NASA Johnson Space Center 
Follow this and additional works at: https://commons.erau.edu/space-congress-proceedings 
Scholarly Commons Citation 
Morrison, Dennis R. Ph.D. and Haddad, Ruwaida S. Ph.D., "Paper Session I-A - Microencapsulation of 
Drugs: New cancer therapies and improved drug delivery from microgravity research" (2003). The Space 
Congress® Proceedings. 13. 
https://commons.erau.edu/space-congress-proceedings/proceedings-2003-40th/april-30-2003/13 
This Event is brought to you for free and open access by 
the Conferences at Scholarly Commons. It has been 
accepted for inclusion in The Space Congress® 
Proceedings by an authorized administrator of Scholarly 
Commons. For more information, please contact 
commons@erau.edu. 
                             
 
       
Microencapsulation of Drugs:  New cancer therapies and improved 
drug delivery derived from microgravity research. 
 
Presented at the 
40th Space Congress 
Cape Canaveral, Florida 
April 30, 2003 
 
                                                          
                                Microcapsules containing anti-tumor drugs made on ISS          
  
 
 
Authored 
 By 
 
 
Dennis R. Morrison, Ph.D.  &  Ruwaida S. Haddad, Ph.D., 
Code SJ/ Biological Systems Office 
NASA –Johnson Space Center, Houston, Texas 77058 
INTERNATIONAL 
SPACE STATION
 
                                                                              
 
Dr. Chiaki Mukai making anti-tumor microcapsule                 Dr. Yuri Onyenfrenko training for MEPS  
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Abstract 
 
New cancer therapies and improved drug delivery derived from 
microgravity research. 
 
Experiments on the ISS include encapsulation of several different anti-cancer drugs, magnetic  triggering 
particles, and encapsulation of genetically engineered DNA.  Eight experiments, using the MEPS-II 
apparatus, were conducted to study the limitations of the fluid shear and g- dependent forces. These 
studies included: 1) formation of anti-tumor microcapsules containing drugs for  “Chemoembolization” of 
vascularized tumors, 2) formation of microcapsules containing a photo-activated drug which can be used 
for Photo Dynamic Therapy of solid tumors by activation with near infrared light (630 nm), 3)  co-
encapsulation of magnetic trigger particles and anti-tumor drugs,  and 4) encapsulation of plasmid DNA.  
The Microencapsulation Electrostatic Processing System (MEPS-II) is an automated apparatus modified 
for use in the ISS Express Rack. The process brings together two immiscible liquids,  restricting fluid 
shear to permitting surface tension forces to predominate at the interface of the fluids. Microcapsules 
were recovered from all 8 experiments and are currently being analyzed for size distribution and drug 
content.  Six NASA Patents have issued from the space research and several more are pending. The 
preliminary results from the Increment 5 - UF-2 experiments have provided new insight into the best 
formulations and conditions required to produce microcapsules of different drugs, esp. special capsules 
containing diagnostic imaging materials and triggered release particles.  Co-encapsulation of multiple 
drugs and Photodynamic Therapy (PDT) drugs has enabled new engineering strategies for production of 
microcapsules on Earth designed for direct delivery into cancer tissues. Other microcapsules have now 
been made for treatment of deep tissue infections, clotting disorders, and to provide delivery of genetic 
engineered materials for potential gene therapy approaches. The MEPS-II apparatus remains in the ISS 
awaiting microencapsulation experiments to be conducted in micro-g, and returned to Earth for analysis.    
 
Microgravity Encapsulation of Drugs & Radiocontrast Medium 
Microgravity research has provided a new under-standing of mechanisms of fluid mechanics, interfacial 
behavior, and biological processing methods that are compromised by gravity-dependent phenomena.  
Multi-layered, liquid microcapsules can be made in a single step by slowly bringing two immiscible 
liquids (of different densities) together under conditions where the surface tension and diffusive forces are 
greater than the convective forces.  The mechanisms of spontaneous formation of large (5 - 300 um) 
microcapsules from oil, water, and hydrocarbon solvents has been studied in micro-g to develop new 
methods to make these unique microcapsules on Earth. 
Antitumor Microcapsules - a new drug delivery system for treating solid tumors.   
Multilayered microcapsules have been made that resemble miniature liquid-filled balloons, containing 
dissolved drugs and a radio-contrast oil. Microcapsules formed in microgravity are designed for 
“chemoembolization” of solid without the usual side effects of systemic chemotherapy.  
Chemoembolization of a splenic tumor is illustrated, wherein, microcapsules containing Cis-Platin or 
Floxuridine anti-tumor drug are released from a catheter into the splenic artery.   
 
The microcapsules are carried in the blood flow into the small arterioles within the tumor wherein they 
pack tightly to form an artificial emboli.  The microcapsules kill the tumor cells by reducing the blood 
flow within the tumor tissues, and releasing the antitumor drug slowly through the permeable outer 
“skin”.  Until recently, these new microcapsules could only be formed under microgravity conditions.  
However, after several Shuttle flights, special formulations and apparatus have been developed that now 
enable microcapsule production on Earth.   
Continuing product development includes microgravity experiments for optimizing drug loading, size 
distributions, and various scale -up production methods. Studies at the Texas A&M College of Veterinary 
Medicine are optimizing the C-T scanning of the microcapsules in rabbit kidneys as a model for 3-D 
imaging in the target tumors. 
 
x- ray of microcapsules packed into renal artery and embolized in the central half of the rabbit kidney  
[~ 2-3 cm. In length] 
     
Multiple Drug Microcapsules 
Multiple drugs can be co-encapsulated in the same microcapsule, but are released at different rates within the 
tissues. This provides opportunities for new, multiple drug delivery if using the special microcapsules.  
Example includes: a) two types of cytotoxic agents which inhibit tumor cell replication, b) a cytotoxic 
drug (Floxur idine) and a photo-actived drug which releases free radicals to destroy cells lining the blood 
vessels within the tumor,  c) a cytotoxic drug (Cis-Platin) which kills the tumor cells, combined with an 
immune stimulant ( Levamisole) that recruits white blood cells to attack the tumor cells.  
Photodynamic Drug Activation and Stimulation of Cellular Repair 
Special microcapsules also are made containing photo-activated drug, Photofrin TM  or Benzo-porphyrin 
derivative (BPD), which can be used for Photo Dynamic  Therapy of solid tumors by activation with near 
infrared light (630 nm). Other applications of Near-Infrared (NIR) light include the ability to: 1) Increase 
the rate of tissue repair of open epidermal and connective tissue wounds, 2), Treat severe mouth ulcers in 
immunologically compromised children following radiotherapy, 3) Treat superficial cuts and severe 
abrasions, in submariners, and 4) Increase the rate of bone regeneration surrounding dental implants. The 
NIR light can penetrate 5-8 inches of tissue to activate cell mechanisms or PDT drugs, without causing 
local heating of the adjacent tissues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NASA also has a current interest in microgravity-induced alterations of cellular mechanisms of wound 
healing esp. those which may involve tissue repair following traumatic injuries, compound fractures, and 
infections. NASA researchers are evaluating NIR light therapy as a potential countermeasure on long 
term space missions and for remote medical care on Earth.  Current studies include cellular mechanisms 
of combined effects of  radioprotectants, cytokine inducers, and model microgravity effects on various 
immune cell functions using the horizontal rotating bioreactors.   
Microencapsulation of cells and cell- aggregates (spheroids). 
Single cells or cell-aggregates can be encapsulated for the purpose of transplantation to provide the 
following: a) secretion of specific agents such as hormones or cytokines, b) reformation of bone c) 
initiation of nerve tissues annealing. 
 
                                                      
                              
           Kidney [BHK 21], single cells encapsulated using NASA proprietary methods  (20x )    
251 um 
140 um 
Fluorescent PhotofrinTM                                           PDT Microcapsules made in space  
 
Different agents can be co-encapsulated in the same microcapsules along with cells or cell-aggregates to 
study molecular mechanisms that inhibit  the immune cytotoxic response. 
 
                                       
Kidney [BHK 21], single cells encapsulated in Alginate, and cultured  for 7 days.  (20x ) 
 
External Triggered (E-T) Microcapsules 
A special purpose microcapsule system has been developed to lyses open the capsules upon the 
application of a harmless external magnetic or ultrasonic field.  This allows for burst release of the drugs 
inside and collapse of the microcapsules when the physicians decide that the slow drug release by 
diffusion through the outer wall is no longer desired. The External-Triggered (E-T) microcapsules are 
made so that each one contains tiny ferromagnetic particles designed to heat up in a magnetic field.  The 
“trigger particles”  become just hot enough to melt a hole in the outer skin thus releasing the contents of 
the microcapsule upon command.  The E-T Microcapsules are designed to be triggered by diagnostic 
levels of Magnetic Resonance Imaging (MRI) fields long after the microcapsules have been injected into 
the tissue.  Current research also includes uses of ultrasonic imaging catheters and drug releasing 
mechanisms. 
 
 
 
Table1. Different drugs and cells encapsulated in space, on earth, and their uses.     
                  
Microcapsules 
Made in space: 
Encapsulated 
Drug/ Cells 
Methods of 
Administration 
Therapeutic  
Use 
Single Drugs Cis- Platin 
Urokinase 
Amoxicillin 
Ciprofloxacin 
Doxcycline 
Reglan 
DNA -(bacterial) 
Intra-Arterial Injection 
I.V. Injection 
I.V. and Tropical 
I.V. or Inhalation 
I.V. or Inhalation 
Intra- Nasal 
Transfection 
Chemoembolize Tumors 
Dissolve Blood Clots 
Resistant Infections 
Inhaled microbial spores 
Inhaled microbial spores 
Microbial vaccines 
Anti-Nausea, Astronauts 
Dual 
Chemotherapy 
Drugs: 
Cis-Platin  +  Floxuridine 
 
Floxuridine + Levamisole  
           (immunostimulant) 
Photofrin + Floxuridine 
BPD-Photodynamic drug 
Intra-Arterial injection 
 
Intra-Arterial injection 
 
Intra-Arterial injection 
Ovarian, bladder, & liver 
tumors 
Colon carcinoma 
 
Esophageal & stomach 
cancer 
  
Additional 
Microcapsule 
made on Earth 
Single cells 
 
Cell-aggregates 
Spheroids 
Transplantation 
 
Transplantation 
Local secretion of 
cytokines and Interferons-? ?
Local secretion of cell  
growth factors 
 
Microgravity                 Optimize formulas, fluid flow rates, temperature                   Optimize production process 
Experiments                  Optimize size distribution , drug loading                                  Help optimize shelf-life 
                                        & deposition of  Ancillary Coatings                                           targeted therapy 
 
 
Current Space Experiments: 
In order to expand the space research, a special Microencapsulation and Electrostatic Processing System 
(MEPS) was designed and flown on STS-95. Three sets of experiments compared the encapsulation 
efficiencies comparing the MEPS, the DMDA type apparatus [ITA, Inc., Exton, PA], and a specially 
modified ADSEP system [SHOT, Inc.,  Greenville, IN].  The results of the STS-95 experiments showed 
that each of the three apparatus had unique advantages depending on the type of experiments.  The MEPS 
showed great promise for space experiments designed understand the limitations of fluid shear, pressure 
& temperature in scale -up and ground-based commercial production.  Therefore, NASA assembled a 
team to construct a second version of the MEPS [MEPS-II] which was designed specifically to operate in 
the ISS.  
 
               Sen. John Glenn conducting microcapsule experiments in ADSEP (STS-95) 
MEPS-II Apparatus Flown on the ISS   
The revised Microencapsulation Electrostatic Processing System (MEPS-II) was built to occupy one-half 
of an Express Rack locker, including rear-air cooling and an improved crew display specifically for 
research in the International Space Station and Shuttle Middeck. The MEPS-II was first flown on UF-1 
[Nov. 2001], but experiment modules were not flown, so the unit was returned for further testing.  
 
 
ISS- Increment 5 Experiments  The first microencapsulation experiments conducted on the 
International Space Station were launched in June 2002 on the UF-2 Mission. The experiments were 
conducted by Dr. Peggy Whitson in July during Increment 5 operations. The Process Chamber Modules 
were returned on STS-111 in November 2002. 
Eight experiments, using the MEPS-II were conducted during the Increment 5 mission. The main research 
focus was to repeat experiments conducted on STS-95 to better understand the limitations of the fluid 
flows and g- dependent forces during the microencapsulation process. These studies included: 1) 
formation of anti-tumor micro-capsules containing drugs for  “Chemoembolization” of vascularized 
tumors, 2) formation of microcapsules containing a photo-activated drug which can be used for Photo 
Dynamic Therapy of solid tumors by activation with near infrared light (630 nm), 3) co-encapsulation of 
magnetic trigger particles and anti-tumor drugs,  and 4) encapsulation of plasmid DNA.  The following 
drugs were encapsulated using three operating processes: 1)  Cis-Platinum (cytotoxic drug),  2)   
Floxuridine (cytotoxic drug),  
3)  Benzoporphyrin derivative (BPD) - photoactivated drug, which destroys tumor, cells upon exposure to 
near infrared light [provided by QLT, Inc.]. 
In two of the four BPD experiments, both liquid drug and crystals of BPD were found many of the 
microcapsules.  Microcapsule sizes ranged from 3 to 95 um [ Note: diameter> 22 um is optimal for 
chemoembolization applications in cancer therapy]. 
        
       Run 5, Texas A & M experiment encapsulating genetic engineered DNA, had the greatest yield of 
capsules ranging from 2 to 20 um in diameter.  Dr. Allison Ficht (TAMU) is analyzing samples of 
microcapsules containing the DNA. 
       Runs 6 & 7 encapsulated two anti-tumor drugs, Cis-Platinum & 5-FU along with magnetic trigger 
particles.  The size range was from 2 to 47 um, the yield was good, and the encapsulation of the trigger 
particles was better than those made on STS-95. 
      During Run 8 – one valve did not open, thus microcapsules were not produced containing the prime 
polymer as a component of the outer skin, however, microcapsules were produced from the coating 
polymer during the electrostatic process [used normally to change the surface charge of microcapsules for 
targeting purposes].  
     
Technology Transfer 
Microencapsulation experiments on the ISS are providing new information to improve manufacturing and 
scale-up production for clinical trials and new therapeutic uses.  NASA has obtained five US Patents on 
the microcapsules, the manufacturing process,  and production apparatus.  Three other related patents are 
pending.  Critical Care Innovations, Inc., (Chantilly, VA) has licensed portions of this technology to 
combine with their Ultrasound catheter and imaging systems to develop a new method of precision 
delivery of anti- cancer drugs directly into solid tumors. IRI (Houston, TX) and NASA-JSC  are 
collaborating with the new Center for Microencapsulation and Drug Delivery at  Texas A&M University  
to  develop new applications for the microcapsules and to optimize microcapsule production for  
commercial manufacturing and marketing.  
 
                     
Microcapsule containing cis-Platin and Floxuridine….fluorescence from drug inside (yellow)            Microencapusles containing bacterial DNA  
Run 7 ISS-UF-2  (JSC/CCI/IRI)                                                                                                             Dr. Allison Ficht, &  Dr. Frank Little, TAMU 
 
This new microcapsule technology presents numerous opportunities for collaborations to develop new 
drug delivery systems for selected medical therapies. Product development is focused on tissue culture, 
animal studies and clinical trials using Earth-based scale -up and production technology.  However, for 
selected projects some space flight experiment opportunities also are available via the NASA Biological 
Systems Office and commercial Space Product Development programs. 
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